Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

This Hot Stock's Sales Are Growing Nearly 4 Times Faster Than Tesla's

By Keith Speights - Dec 15, 2020 at 6:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

But its share price has risen only one-fifth as much as the electric vehicle giant so far in 2020.

Whatever you think about Tesla ( TSLA -0.47% ), there's no question that the electric vehicle (EV) pioneer has enjoyed a remarkable year. Its shares have skyrocketed more than 660%. The company generated record revenue and profits. Tesla was even selected to be added to the S&P 500 index.

So, sure, Tesla deserves some big-time kudos. But there's another hot stock delivering sales growth that blows Tesla away. It's also a lot smaller than the EV giant. This stock has received plenty of attention from investors this year, although not nearly to the extent that Tesla has. What is this mystery stock? None other than leading telehealth provider Teladoc Health ( TDOC 1.01% ).

Person with laptop showing a doctor on the screen.

Image source: Getty Images.

Faster than a speeding Model S

While Tesla is selling more of its cars than ever before, its sales growth simply doesn't hold a candle to Teladoc's. The following chart compares the two companies' trailing-12-month revenue growth. Tesla's rate of growth is good, but Teladoc's sales are zooming higher faster than a speeding Model S.

TSLA Revenue (TTM) Chart

TSLA Revenue (TTM) data by YCharts

Why is Teladoc's revenue growing nearly four times faster than Tesla's? The credit primarily goes to the COVID-19 pandemic.

The shelter-in-place orders in much of the U.S. earlier this year caused a surge in telehealth visits. During the first nine months of 2020, Teladoc's total visits soared 163% to 7.6 million.

Don't think for a second that Teladoc's momentum is running out, though. Actually, the company is experiencing accelerated growth. Teladoc reported that its total visits more than tripled in the third quarter, driving revenue up 109% year over year.

Tesla had a great Q3, too, but its 42% year-over-year revenue growth still lagged well behind Teladoc's performance.

Different lanes

Some might object to the idea of comparing Teladoc with Tesla. After all, the companies operate in completely different lanes. The electric vehicle business isn't anything like the telehealth services business. That's true, but every stock competes with every other stock for investors' hard-earned money, in a sense. 

Tesla is clearly winning the race against Teladoc right now. Its stock has soared nearly five times more than Teladoc's stock has in 2020.

It certainly doesn't hurt Tesla's appeal to investors that the company is already profitable. Despite the huge jump in revenue this year, Teladoc still hasn't achieved profitability.

There's also probably a perception gap about the post-pandemic possibilities for each company. Tesla could receive a boost when the COVID-19 worries fade and people have more money to spend on cars. The incoming Biden administration's focus on climate change could also help push consumers toward Tesla's electric vehicles and solar roofs. On the other hand, some worry that the end of the pandemic could throttle Teladoc's growth as patients return to visiting healthcare professionals in person.

Electric opportunity

I think worries about Teladoc in a post-pandemic world are misplaced. Surveys show that most Americans like using telehealth and want the option even after the coronavirus crisis is behind us.

Thanks to its recent acquisition of Livongo Health, Teladoc now should be even more attractive to corporate customers. Livongo's digital health platform for helping patients manage chronic conditions such as diabetes and hypertension is a perfect fit for Teladoc's core telehealth services.

Teladoc estimates that its total addressable market now tops $120 billion per year in the U.S. alone. The company currently has a market share of less than 1%. The healthcare stock has tremendous potential as virtual care, including telehealth and remote disease management, gain adoption.

Tesla's accolades are well-deserved, but I think Teladoc Health, with its faster-growing revenue and much smaller market cap, also has an electric opportunity ahead. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
TDOC
$93.36 (1.01%) $0.93
Tesla, Inc. Stock Quote
Tesla, Inc.
TSLA
$1,010.25 (-0.47%) $-4.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.